Intra-articular injection of kartogenin-conjugated polyurethane nanoparticles attenuates the progression of osteoarthritis

Bibliographic Details
Title: Intra-articular injection of kartogenin-conjugated polyurethane nanoparticles attenuates the progression of osteoarthritis
Authors: Wenshuai Fan, Jinghuan Li, Liu Yuan, Jifei Chen, Zhe Wang, Yiming Wang, Changan Guo, Xiumei Mo, Zuoqin Yan
Source: Drug Delivery, Vol 25, Iss 1, Pp 1004-1012 (2018)
Publisher Information: Taylor & Francis Group, 2018.
Publication Year: 2018
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: osteoarthritis, intra-articular injection, kartogenin, polyurethane nanoparticles, Therapeutics. Pharmacology, RM1-950
More Details: Osteoarthritis (OA) is the most common form of joint disease and a leading cause of physical disability, there is an urgent need to attenuate the progression of OA. Intra-articular (IA) injection is an effective treatment for joints diseases, however, the therapeutic effects mostly depend on the efficacy of drug duration in joints. Drug delivery system can provide drug-controlled release and reduce the number of IA injection. In this study, amphiphilic polyurethanes with pendant amino group were synthesized and amide bonds were formed between the amine group of polyurethane and the carboxyl group of kartogenin (KGN), a small molecular reported to show both regenerative and protective effects on cartilage. Our results showed that KGN-conjugated polyurethane nanoparticles (PN-KGN) were spherical and regular in shape with an average size of 25 nm and could sustained and controlled release of KGN in vitro. PN-KGN showed no cytotoxicity and pro-inflammatory effects on chondrocytes. The therapeutic effects in OA model showed that IA injection of KGN could attenuate the progress of OA, however, the cartilage degeneration became obviously at 12 weeks with matrix loss and vertical fissures. By contrast, IA injection of PN-KGN showed less cartilage degeneration with significant lower OARSI scores even at 12 weeks, indicating PN-KGN could further arrest the development of OA. Immunohistochemistry also validated that IA injection of PN-KGN retained the normal compositions of cartilage matrix, with much stronger Col II staining and less Col I staining. In conclusion, IA injection of PN-KGN is a better potential strategy to treat OA, with long-time cartilage protection and less IA injections.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1071-7544
1521-0464
10717544
Relation: https://doaj.org/toc/1071-7544; https://doaj.org/toc/1521-0464
DOI: 10.1080/10717544.2018.1461279
Access URL: https://doaj.org/article/ea8752dcc47f477e9c5f9bca21a8c881
Accession Number: edsdoj.8752dcc47f477e9c5f9bca21a8c881
Database: Directory of Open Access Journals
Full text is not displayed to guests.
More Details
ISSN:10717544
15210464
DOI:10.1080/10717544.2018.1461279
Published in:Drug Delivery
Language:English